JP5792718B2 - 処置前治療用メタロプロテアーゼ準備パック - Google Patents
処置前治療用メタロプロテアーゼ準備パック Download PDFInfo
- Publication number
- JP5792718B2 JP5792718B2 JP2012517694A JP2012517694A JP5792718B2 JP 5792718 B2 JP5792718 B2 JP 5792718B2 JP 2012517694 A JP2012517694 A JP 2012517694A JP 2012517694 A JP2012517694 A JP 2012517694A JP 5792718 B2 JP5792718 B2 JP 5792718B2
- Authority
- JP
- Japan
- Prior art keywords
- zinc
- treatment
- therapeutic
- toxin
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03008—3-Phytase (3.1.3.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03026—4-Phytase (3.1.3.26), i.e. 6-phytase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/709—Toxin induced
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Description
本願の発明者は、各個人における利用可能な細胞内亜鉛貯蔵の差が、一部の患者におけるボツリヌス菌応答性の欠如を説明し得ると推論した。前記仮説の初期調査では、亜鉛の補給は食料供給源によって行われた。安全性、低コスト、入手し易さ、および一般的了解に基づいて、生物学的に利用可能なZn2+の食事供給源として七面鳥肉が選択された。患者が消費するように指示された七面鳥肉の量は、40mgの1日量、すなわち推奨される1日の摂取量の約2.5倍を提供するように算定された。多くのこれらの患者は、ボツリヌス毒素に対して応答が乏しく、そのため眼瞼痙攣の症状の制御を達成するのが病歴的に困難であったと考えられた。結果は、亜鉛補給は、補給がない状態の同一患者において効果がなかったのと同一のボツリヌス毒素供給源および用量を用いて、眼瞼痙攣の著しく有効な治療をもたらすことを示した。
亜鉛吸収の阻害におけるフィチン酸塩の役割を考慮して、本発明の一態様では、亜鉛の経口吸収は、フィチン酸(イノシトールヘキサキスホスファート)を加水分解し、亜鉛の経口吸収を高めるフィターゼの経口投与によって、増大される。フィターゼは、現在、カルシウム、マグネシウム、鉄および亜鉛のような2価カチオンの吸収を増大させるように設計された栄養補助食品として栄養補助食品市場において入手可能である。これらの2価カチオンは、トウモロコシ、トウモロコシ副産物、豆果、大豆および穀物のような植物性食物中に存在する植物フィチン酸と不溶性の複合体を形成して、それらを利用不可能にする。フィターゼは、フィチン酸(イノシトールヘキサキスホスファート)からリン酸塩を利用可能にする目的で動物飼料への添加物として用いられている。動物飼料へのフィターゼの添加は、低フィチン酸塩の食餌においてさえ、有利であることが開示されている。例えば、アスペルギルスからのフィターゼを含有する低フィチン酸塩飼料組成物を開示している国際出願公開第WO9949740号を参照されたい。「Phytase Combinations」と題された国際出願公開第WO9830681号は、異なる位置特異性を有する少なくとも2種のフィターゼの組み合わせが、フィチン酸塩のリン(phytate phosphorous)の放出においてより有効であることを開示している。
Claims (7)
- カプセルまたは錠剤の形態にある一定量の亜鉛イオンを含む補給剤であって、前記補給剤は、治療用メタロプロテアーゼの活性に必要とされると判断された少なくとも1種の亜鉛イオンを含有し、前記補給剤は、患者の治療用メタロプロテアーゼによる治療の直前に設定される同補給剤の補充期間中に前記亜鉛イオンを1日あたりに供給するのに十分な量で前記患者に投与される、補給剤と、
前記亜鉛イオンを含む補給剤をとり、かつフィチン酸塩の摂取を低減するように患者に指示する使用説明書と、を含み、
前記治療用メタロプロテアーゼはクロストリジウム神経毒素である、処置前治療用メタロプロテアーゼ準備パック。 - 前記一定量の亜鉛イオンを含む補給剤は、亜鉛タンパク化合物と、有機分子を有する亜鉛キレート化合物および塩のうちの少なくとも一方と、亜鉛アミノ酸複合体と、のうちの1つ以上から選択される有機亜鉛形態を含む、請求項1に記載の処置前治療用メタロプロテアーゼ準備パック。
- 前記補給剤の投与は、任意の形態の、局所投与、舌下投与、浣腸剤、経皮投与、又は直腸投与のうちの1つ以上を含む、請求項1に記載の処置前治療用メタロプロテアーゼ準備パック。
- 前記亜鉛イオンを含む補給剤は、十分な量のフィターゼをさらに含む、請求項1に記載の処置前治療用メタロプロテアーゼ準備パック。
- 前記亜鉛イオンを含む補給剤は、有機形態または無機形態の亜鉛を、患者のクロストリジウム神経毒素による治療の直前の前記補充期間中に、1日あたり10〜400mgの元素亜鉛を供給するのに十分な用量で含む、請求項1に記載の処置前治療用メタロプロテアーゼ準備パック。
- 前記補充期間は、患者のクロストリジウム神経毒素による治療の直前の少なくとも4日間である、請求項1乃至5のいずれか1項に記載の処置前治療用メタロプロテアーゼ準備パック。
- 前記補充期間は、患者のクロストリジウム神経毒素による治療の直前の4日間未満である、請求項1乃至5のいずれか1項に記載の処置前治療用メタロプロテアーゼ準備パック。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21993209P | 2009-06-24 | 2009-06-24 | |
US61/219,932 | 2009-06-24 | ||
US12/821,370 | 2010-06-23 | ||
US12/821,370 US8591884B2 (en) | 2009-06-24 | 2010-06-23 | Compositions and methods for enhancing metal ion dependent drug therapies |
PCT/US2010/039674 WO2011005577A1 (en) | 2009-06-24 | 2010-06-23 | Zinc supplementation to increase responsiveness to metalloprotease therapy |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012531421A JP2012531421A (ja) | 2012-12-10 |
JP2012531421A5 JP2012531421A5 (ja) | 2013-08-01 |
JP5792718B2 true JP5792718B2 (ja) | 2015-10-14 |
Family
ID=42543131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012517694A Active JP5792718B2 (ja) | 2009-06-24 | 2010-06-23 | 処置前治療用メタロプロテアーゼ準備パック |
Country Status (8)
Country | Link |
---|---|
US (3) | US8591884B2 (ja) |
EP (1) | EP2445509B1 (ja) |
JP (1) | JP5792718B2 (ja) |
KR (1) | KR101595033B1 (ja) |
CA (1) | CA2766649C (ja) |
ES (1) | ES2615281T3 (ja) |
RU (1) | RU2540520C2 (ja) |
WO (1) | WO2011005577A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011005577A1 (en) * | 2009-06-24 | 2011-01-13 | Soparkar Charles N S | Zinc supplementation to increase responsiveness to metalloprotease therapy |
US9498421B2 (en) * | 2012-12-19 | 2016-11-22 | Colgate-Palmolive Company | Two component compositions containing tetrabasic zinc-amino acid halide complexes and cysteine |
US9750670B2 (en) * | 2012-12-19 | 2017-09-05 | Colgate-Palmolive Company | Zinc amino acid complex with cysteine |
JP5976955B2 (ja) | 2012-12-19 | 2016-08-24 | コルゲート・パーモリブ・カンパニーColgate−Palmolive Company | 酸化亜鉛およびトリメチルグリシンを含むオーラルケア製品 |
CN104853721B (zh) | 2012-12-19 | 2017-10-27 | 高露洁-棕榄公司 | 锌精氨酸/赖氨酸卤化物 |
MX368740B (es) | 2012-12-19 | 2019-10-14 | Colgate Palmolive Co | Gel oral que comprende un complejo de zinc - aminoacidos. |
US9572756B2 (en) | 2012-12-19 | 2017-02-21 | Colgate-Palmolive Company | Teeth whitening methods, visually perceptible signals and compositions therefor |
US9757316B2 (en) | 2012-12-19 | 2017-09-12 | Colgate-Palmolive Company | Zinc-lysine complex |
US9861563B2 (en) | 2012-12-19 | 2018-01-09 | Colgate-Palmolive Company | Oral care products comprising tetrabasic zinc chloride and trimethylglycine |
AU2012397267B2 (en) | 2012-12-19 | 2015-10-08 | Colgate-Palmolive Company | Oral care compositions comprising zinc amino acid halides |
CA2892411C (en) | 2012-12-19 | 2019-09-10 | Colgate-Palmolive Company | Antiperspirant products with protein and antiperspirant salts |
WO2014099164A2 (en) * | 2012-12-19 | 2014-06-26 | Colgate-Palmolive Company | Zinc amino acid halide complex with cysteine |
AU2012397266B2 (en) | 2012-12-19 | 2015-09-24 | Colgate-Palmolive Company | Oral care products comprising a tetrabasic zinc - amino acid - halide complex |
RU2638791C2 (ru) | 2012-12-19 | 2017-12-15 | Колгейт-Палмолив Компани | Композиция с галогенидными предшественниками аминокислоты/триметилглицина цинка |
US9504858B2 (en) | 2012-12-19 | 2016-11-29 | Colgate-Palmolive Company | Zinc amino acid halide complex with cysteine |
US10494589B2 (en) * | 2012-12-19 | 2019-12-03 | Colgate-Palmolive Company | Method for indicating time for washing or indicating delivery of antibacterial agent |
WO2014098822A1 (en) | 2012-12-19 | 2014-06-26 | Colgate-Palmolive Company | Zinc amino acid halide mouthwashes |
US9675823B2 (en) | 2012-12-19 | 2017-06-13 | Colgate-Palmolive Company | Two component compositions containing zinc amino acid halide complexes and cysteine |
US10188112B2 (en) | 2012-12-19 | 2019-01-29 | Colgate-Palmolive Company | Personal cleansing compositions containing zinc amino acid/trimethylglycine halide |
US10912796B2 (en) | 2013-03-14 | 2021-02-09 | Albion Laboratories, Inc. | Phosphorus-sparing nutritional composition |
JP6185215B2 (ja) | 2015-06-12 | 2017-08-23 | Jfeミネラル株式会社 | 皮膚創傷または皮膚荒れ治療剤 |
CN109803673A (zh) | 2016-09-13 | 2019-05-24 | 阿勒根公司 | 非蛋白质梭菌毒素组合物 |
CN110035761A (zh) | 2016-12-09 | 2019-07-19 | 杰富意矿物股份有限公司 | 锌离子缓释性优异的氯化锌氢氧化物及其制造方法 |
KR20190038292A (ko) * | 2017-09-29 | 2019-04-08 | 한국프라임제약주식회사 | 효능 지속시간이 연장된 보툴리눔 독소 조성물 |
TW202348248A (zh) * | 2022-02-15 | 2023-12-16 | 德商梅茲製藥有限兩合公司 | 液體製劑及其製備方法與用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ289014B6 (cs) | 1989-09-27 | 2001-10-17 | Dsm N. V. | Vyčiątěná a izolovaná sekvence DNA kódující fungální fytázu, konstrukt pro expresi, vektory a transformované hostitelské buňky a způsob produkce fytázy |
CA2138020C (en) | 1992-06-23 | 1999-02-16 | Eric A. Johnson | Pharmaceutical composition containing botulinum b complex |
US6488956B1 (en) * | 1994-06-20 | 2002-12-03 | Drugtech Corporation | Multi-vitamin and mineral supplements for women |
AU5477898A (en) | 1997-01-09 | 1998-08-03 | Novo Nordisk A/S | Phytase combinations |
US5770217A (en) | 1997-07-02 | 1998-06-23 | Atlatl, Inc. | Dietary supplement for hematological, immune and appetite enhancement |
AU748986B2 (en) | 1998-04-01 | 2002-06-13 | Dsm N.V. | Application of phytase in feed having low content of phytate |
US20060269575A1 (en) | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US20040086532A1 (en) | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
EP1594523B1 (en) | 2002-12-20 | 2009-03-25 | Botulinum Toxin Research Associates, Inc. | Pharmaceutical compositions comprising botulinum toxin and human serum albumin |
US7148041B2 (en) | 2003-09-25 | 2006-12-12 | Allergan, Inc. | Animal product free media and processes for obtaining a botulinum toxin |
JP2008521387A (ja) * | 2004-11-29 | 2008-06-26 | ビーエーエスエフ ソシエタス・ヨーロピア | 酵素製剤 |
US8137677B2 (en) | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
WO2011005577A1 (en) * | 2009-06-24 | 2011-01-13 | Soparkar Charles N S | Zinc supplementation to increase responsiveness to metalloprotease therapy |
-
2010
- 2010-06-23 WO PCT/US2010/039674 patent/WO2011005577A1/en active Application Filing
- 2010-06-23 ES ES10730300.0T patent/ES2615281T3/es active Active
- 2010-06-23 CA CA2766649A patent/CA2766649C/en active Active
- 2010-06-23 RU RU2012102322/15A patent/RU2540520C2/ru active
- 2010-06-23 JP JP2012517694A patent/JP5792718B2/ja active Active
- 2010-06-23 US US12/821,370 patent/US8591884B2/en active Active
- 2010-06-23 EP EP10730300.0A patent/EP2445509B1/en active Active
- 2010-06-23 KR KR1020127001685A patent/KR101595033B1/ko active IP Right Grant
-
2013
- 2013-10-30 US US14/067,654 patent/US8916150B2/en active Active
-
2014
- 2014-11-24 US US14/551,291 patent/US9463224B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20100330163A1 (en) | 2010-12-30 |
US8591884B2 (en) | 2013-11-26 |
JP2012531421A (ja) | 2012-12-10 |
ES2615281T3 (es) | 2017-06-06 |
US9463224B2 (en) | 2016-10-11 |
EP2445509B1 (en) | 2016-11-30 |
RU2540520C2 (ru) | 2015-02-10 |
RU2012102322A (ru) | 2013-07-27 |
US20140056869A1 (en) | 2014-02-27 |
US20150086528A1 (en) | 2015-03-26 |
EP2445509A1 (en) | 2012-05-02 |
WO2011005577A1 (en) | 2011-01-13 |
KR20120107915A (ko) | 2012-10-04 |
KR101595033B1 (ko) | 2016-02-17 |
US8916150B2 (en) | 2014-12-23 |
CA2766649A1 (en) | 2011-01-13 |
CA2766649C (en) | 2016-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5792718B2 (ja) | 処置前治療用メタロプロテアーゼ準備パック | |
US7648957B2 (en) | Nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction | |
JP6797305B2 (ja) | ボツリヌス毒素および安定化剤を含む液状剤形およびその製造方法 | |
JP2004536778A (ja) | 変化した生物学的持続性を有する改変クロストリジウム神経毒 | |
EP2793613A1 (en) | Protease enzymes for increased protein digestion rate and absorption and methods of using the same | |
JPWO2011016220A1 (ja) | ジペプチジルペプチダーゼ−4阻害剤 | |
Guilliams et al. | Meal-Time Supplementation with Betaine HCl for Functional Hypochlorhydria: What is the Evidence? | |
KR20140020951A (ko) | 피부 미용제 | |
Wu et al. | Effects of ultra-high pressure treatment on angiotensin-converting enzyme (ACE) inhibitory activity, antioxidant activity, and physicochemical properties of milk fermented with Lactobacillus delbrueckii QS306 | |
JP5250302B2 (ja) | 血糖上昇抑制剤 | |
EP2480250B1 (en) | Compositions comprising botulinum toxin A or B for use in the treatment of osteoporosis | |
JP6713981B2 (ja) | リパーゼ阻害剤 | |
WO2006093166A1 (ja) | 米ペプチドを含む酵素処理物、およびそれを含有する生理活性作用改善組成物 | |
EP1633377A1 (en) | A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein | |
AU2012319579B2 (en) | Sense-improving agent | |
JP3605528B2 (ja) | 体重増加抑制剤 | |
WO2021159031A1 (en) | Digestive aid for plant-based proteins | |
Shimizu et al. | History and scope of functional foods in Japan | |
WO2014052880A1 (en) | Nutritional supplements for eye health and related methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130612 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130612 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140708 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141006 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150106 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150304 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150707 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150806 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5792718 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |